SymBio Pharmaceuticals's ROE % for the quarter that ended in Dec. 2025 was -321.24%. SymBio Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2025 was 4.65.
SymBio Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -69.08%.
SymBio Pharmaceuticals ROE % Adjusted to Book Value Related Terms
SymBio Pharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for SymBio Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SymBio Pharmaceuticals ROE % Adjusted to Book Value Chart
SYMQY vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -69.08% mean?
SymBio Pharmaceuticals (SYMQY) has a ROE % Adjusted to Book Value of -69.08% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' ROE % Adjusted to Book Value too high?
SymBio Pharmaceuticals' current ROE % Adjusted to Book Value is -69.08%. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' ROE % Adjusted to Book Value compare to ZTS and UTHR?
SymBio Pharmaceuticals' ROE % Adjusted to Book Value of -69.08% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current ROE % Adjusted to Book Value is -69.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current ROE % Adjusted to Book Value of -69.08%. The stock's GF Value™ is $0.44, compared to a current price of $0.56 — trading 26.8% above its estimated fair value. The current ROE % Adjusted to Book Value is -69.08%. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current ROE % Adjusted to Book Value is -69.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of $0.56 is trading 26.8% above its estimated GF Value™ of $0.44.
Key valuation signals for SYMQY:
ROE % Adjusted to Book Value: -69.08%
GF Value™: $0.44 vs. price of $0.56 (26.8% above fair value)
No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score
Get the complete analysis for SYMQY
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYMQY has been successfully added to your 
